Anti-inflammatory drugs and risk of Alzheimer's Disease: An updated systematic review and meta-analysis

Journal of Alzheimer's Disease

Volumn 44, Issue 2, 2015, Pages 385-396

  Wang, Jun ^a   Tan, Lan ^a,b   Wang, Hui Fu ^b   Tan, Chen Chen ^a   Meng, Xiang Fei ^a   Wang, Chong ^a   Tang, Shao Wen ^b   Yu, Jin Tai ^a,b,c  

^a QINGDAO UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; anti inflammatory drug; aspirin; meta analysis; NSAIDs; prevention; systematic review

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; BETAMETHASONE; CELECOXIB; CORTICOSTEROID; CORTISONE; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; DICLOFENAC; ETODOLAC; ETORICOXIB; HYDROCORTISONE; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; LUMIRACOXIB; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PREDNISONE; ROFECOXIB; STEROID; TENOXICAM; NOOTROPIC AGENT;

ALZHEIMER DISEASE; DRUG USE; HUMAN; LONG TERM CARE; META ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION; RISK;

ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; NOOTROPIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 84921531052     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-141506     Document Type: Review

References (53)

1. Yu JT, Tan L, Hardy J (2014) Apolipoprotein E in Alzheimer's disease: An update. Annu Rev Neurosci 37, 79-100.
2. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, VanMuiswinkel FL,Veerhuis R,Walker D,Webster S,Wegrzyniak B,Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-421.
3. McGeer EG, McGeer PL (2003) Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 27, 741-749.
4. Wang J, Yu JT, Tan MS, Jiang T, Tan L (2013) Epigenetic mechanisms in Alzheimer's disease: Implications for pathogenesis and therapy. Ageing Res Rev 12, 1024-1041.
5. Tan MS, Yu JT, Jiang T, Zhu XC, Tan L (2013) The NLRP3 inflammasome in Alzheimer's disease. Mol Neurobiol 48, 875-882.
6. De Felice FG (2013) Alzheimer's disease and insulin resistance: Translating basic science into clinical applications. J Clin Invest 123, 531-539.
7. Ferreira ST, Clarke JR, Bomfim TR, De Felice FG (2014) Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease. Alzheimers Dement 10, S76-S83.
8. Takeda S, Sato N, Ikimura K, Nishino H, Rakugi H, Morishita R (2013) Increased blood-brain barrier vulnerability to systemic inflammation in an Alzheimer disease mouse model. Neurobiol Aging 34, 2064-2070.
9. Swardfager W, Lanctot K, Rothenburg L, Wong A, Cappell J, Herrmann N (2010) A meta-analysis of cytokines in Alzheimer's disease. Biol Psychiatry 68, 930-941.
10. Griffin WS, Stanley LC, Ling C, White L, MacLeod V, Perrot LJ, White CL, 3rd, Araoz C (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 86, 7611-7615.
11. Grammas P,Ovase R(2001) Inflammatory factors are elevated in brain microvessels in Alzheimer's disease. Neurobiol Aging 22, 837-842.
12. Etminan M, Gill S, Samii A (2003) Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: Systematic review and meta-analysis of observational studies. BMJ 327, 128.
13. Szekely CA, Green RC, Breitner JC, Ostbye T, Beiser AS, Corrada MM, Dodge HH, Ganguli M, Kawas CH, Kuller LH, Psaty BM, Resnick SM, Wolf PA, Zonderman AB, Welsh-Bohmer KA, Zandi PP (2008) No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 70, 2291-2298.
14. Szekely CA, Thorne JE, Zandi PP, Ek M, Messias E, Breitner JC, Goodman SN (2004) Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: A systematic review. Neuroepidemiology 23, 159-169.
15. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med 6, e1000097.
16. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283, 2008-2012.
17. Wells G Shea B, O'Connell D, Peterson. J, Welch V, Losos M, Tugwell P (Accessed March 4, 2009) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Health Research Institute. Available at: http://www. ohri.ca/programs/clinical epidemiology/oxford.htm.
18. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF,Weeks L, Sterne JA (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343, d5928.
19. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7, 177-188.
20. Wang J, Yu JT, Wang HF, Meng XF, Wang C, Tan CC, Tan L. (2014) Pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease: A systematic review and meta-analysis. J Neurol Neurosurg Psychiatry, doi: 10.1136/jnnp-2014-308112.
21. Wang HF, Yu JT, Tang SW, Jiang T, Tan CC, Meng XF,Wang C,Tan MS,Tan L. (2014) Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: Systematic review with meta-analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry, doi: 10.1136/jnnp-2014-307659.
22. Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21, 1539-1558.
23. Tan CC, Yu JT,Wang HF, Tan MS, Meng XF,Wang C, Jiang T, Zhu XC, Tan L (2014) Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: A systematic review and meta-analysis. J Alzheimers Dis 41, 615-631.
24. Lindsay J, Laurin D, Verreault R, Hebert R, Helliwell B, Hill GB, McDowell I (2002) Risk factors for Alzheimer's disease: A prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol 156, 445-453.
25. Côté S, Carmichael PH, Verreault R, Lindsay J, Lefebvre J, Laurin D(2012) Nonsteroidal anti-inflammatory drug use and the risk of cognitive impairment and Alzheimer's disease. Alzheimers Dement 8, 219-226.
26. Breitner JC, Welsh KA, Helms MJ, Gaskell PC, Gau BA, Roses AD, Pericak-Vance MA, Saunders AM (1995) Delayed onset of Alzheimer's disease with nonsteroidal antiinflammatory and histamine H2 blocking drugs. Neurobiol Aging 16, 523-530.
27. Stewart WF, Kawas C, Corrada M, Metter EJ (1997) Risk of Alzheimer's disease and duration of NSAID use. Neurology 48, 626-632.
28. in t'Veld BA, Ruitenberg A, Hofman A, Launer LJ, van Duijn CM,Stijnen T, Breteler MM,Stricker BH(2001) Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 345, 1515-1521.
29. Zandi PP, Anthony JC, Hayden KM,Mehta K, Mayer L, Breitner JC (2002) Reduced incidence ofADwith NSAID but not H2 receptor antagonists: The Cache County Study. Neurology 59, 880-886.
30. Landi F, Cesari M, Onder G, Russo A, Torre S, Bernabei R (2003) Non-steroidal anti-inflammatory drug (NSAID) use and Alzheimer disease in community-dwelling elderly patients. Am J Geriatr Psychiatry 11, 179-185.
31. Nilsson SE, Johansson B, Takkinen S, Berg S, Zarit S, McClearn G, Melander A (2003) Does aspirin protect against Alzheimer's dementia? A study in a Swedish populationbased sample aged≥80 years. Eur J Clin Pharmacol 59, 313-319.
32. Cornelius C, Fastbom J, Winblad B, Viitanen M (2004) Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E epsilon 4 allele in an elderly population. Neuroepidemiology 23, 135-143.
33. Arvanitakis Z, Grodstein F, Bienias JL, Schneider JA, Wilson RS, Kelly JF, Evans DA, Bennett DA (2008) Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology 70, 2219-2225.
34. Fischer P, Zehetmayer S, Jungwirth S, Weissgram S, Krampla W, Hinterberger M, Torma S, Rainer M, Huber K, Hoenigschnabl S, Gelpi E, Bauer K, Leitha T, Bauer P, Tragl KH (2008) Risk factors for Alzheimer dementia in a community-based birth cohort at the age of 75 years. Dement Geriatr Cogn Disord 25, 501-507.
35. Szekely CA, Breitner JC, Fitzpatrick AL, Rea TD, Psaty BM, Kuller LH, Zandi PP (2008) NSAID use and dementia risk in the Cardiovascular Health Study: Role of APOE and NSAID type. Neurology 70, 17-24.
36. Breitner JC, Haneuse SJ,Walker R, Dublin S, Crane PK, Gray SL, Larson EB (2009) Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 72, 1899-1905.
37. Breitner JC, Gau BA, Welsh KA, Plassman BL, McDonald WM, Helms MJ, Anthony JC (1994) Inverse association of anti-inflammatory treatments and Alzheimer's disease: Initial results of a co-twin control study. Neurology 44, 227-232.
38. Beard CM, Waring SC, O'Brien PC, Kurland LT, Kokmen E (1998) Nonsteroidal anti-inflammatory drug use and Alzheimer's disease: A case-control study in Rochester, Minnesota, 1980 through 1984. Mayo Clin Proc 73, 951-955.
39. Yip AG, Green RC, Huyck M, Cupples LA, Farrer LA (2005) Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: The MIRAGE Study. BMC Geriatr 5, 2.
40. Vlad SC, Miller DR,Kowall NW, Felson DT(2008) Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70, 1672-1677.
41. GroupADAPT (2013) Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers Dement 9, 714-723.
42. Millett GA, Flores SA, Marks G, Reed JB, Herbst JH (2008) Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: A metaanalysis. JAMA 300, 1674-1684.
43. Gagne JJ, Power MC (2010) Anti-inflammatory drugs and risk of Parkinson disease: A meta-analysis. Neurology 74, 995-1002.
44. Szekely CA, Zandi PP (2010) Non-steroidal antiinflammatory drugs and Alzheimer's disease: The epidemiological evidence. CNS Neurol Disord Drug Targets 9, 132-139.
45. Wang C, Yu JT, Wang HF, Jiang T, Tan CC, Meng XF, Soares HD, Tan L (2014) Meta-analysis of peripheral blood apolipoprotein E levels in Alzheimer's disease. PLoS One 9, e89041.
46. Yasojima K, Schwab C, McGeer EG, McGeer PL (1999) Distribution of cyclooxygenase-1 and cyclooxygenase-2mRNAs and proteins in human brain and peripheral organs. Brain Res 830, 226-236.
47. Ho L, Pieroni C, Winger D, Purohit DP, Aisen PS, Pasinetti GM (1999) Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. J Neurosci Res 57, 295-303.
48. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, Bulter T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH (2001) A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 414, 212-216.
49. Yan Q, Zhang J, Liu H, Babu-Khan S, Vassar R, Biere AL, Citron M, LandrethG(2003) Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J Neurosci 23, 7504-7509.
50. Netland EE, Newton JL, Majocha RE, Tate BA (1998) Indomethacin reverses the microglial response to amyloid beta-protein. Neurobiol Aging 19, 201-204.
51. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, Ozols VV, Jessing KW, Zavitz KH, Koo EH, Golde TE (2003) NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 112, 440-449.
52. Combs CK, Bates P, Karlo JC, Landreth GE(2001) Regulation of beta-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor alpha. Neurochem Int 39, 449-457.
53. Landreth GE, Heneka MT (2001) Anti-inflammatory actions of peroxisome proliferator-activated receptor gamma agonists in Alzheimer's disease. Neurobiol Aging 22, 937-944.